公开(公告)号：US20240301079A1

公开(公告)日：2024-09-12

申请号：US18540730

申请日：2023-12-14

申请人： Roche GlycArt AG

发明人： Pablo UMAÑA ,  Peter BRÚNKER ,  Claudia FERRARA KOLLER ,  Tobias SUTER ,  Ursula PÚNTENER ,  Ekkehard MÓSSNER

IPC分类号： C07K16/28 ,  A61K39/00 ,  C12N9/10 ,  C12N15/11 ,  C12N15/63

CPC分类号： C07K16/2887 ,  C12N9/1051 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/01 ,  C12N15/11 ,  C12N15/63 ,  C12Y204/01144 ,  Y10S530/808 ,  Y10S530/866 ,  Y10S530/867

摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

公开(公告)号：US20160369240A1

公开(公告)日：2016-12-22

申请号：US15122311

申请日：2015-03-03

申请人： SIGMA-ALDRICH CO. LLC

发明人： Nan LIN ,  Joaquina MASCARENHAS ,  Audrey CHANG ,  David ONIONS ,  Henry GEORGE ,  Kevin KAYSER

IPC分类号： C12N5/071 ,  C12N9/10

CPC分类号： C12N5/0682 ,  C12N5/00 ,  C12N9/1051 ,  C12N2501/724 ,  C12N2510/02 ,  C12N2720/12011 ,  C12N2750/14311 ,  C12Y204/01101 ,  C12Y204/01144 ,  C12Y204/01155

摘要： The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.

摘要翻译： 本发明提供已经进行遗传工程改造的哺乳动物细胞系，使得这种细胞系能够抵抗病毒进入和/或繁殖，并提供使用所述细胞系减少或防止生物制备系统的病毒污染的方法。

公开(公告)号：US20160075793A1

公开(公告)日：2016-03-17

申请号：US14815562

申请日：2015-07-31

申请人： Roche Glycart AG

发明人： Pablo UMAÑA ,  Peter BRÜNKER ,  Claudia FERRARA KOLLER ,  Tobias SUTER ,  Ursula PÜNTENER ,  Ekkehard MÖSSNER

IPC分类号： C07K16/28

CPC分类号： C07K16/2887 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/01 ,  C12N9/1051 ,  C12N15/11 ,  C12N15/63 ,  C12Y204/01144 ,  Y10S530/808 ,  Y10S530/866 ,  Y10S530/867

摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

摘要翻译： 本发明涉及抗原结合分子（ABM）。 在具体实施方案中，本发明涉及重组单克隆抗体，包括对人CD20特异性的嵌合，灵长类或人源化抗体。 此外，本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

公开(公告)号：US08859234B2

公开(公告)日：2014-10-14

申请号：US13759925

申请日：2013-02-05

申请人： Roche GlycArt AG

发明人： Pablo Umaña ,  Peter Bruenker ,  Claudia Ferrara ,  Tobias Suter

IPC分类号： C12P21/04 ,  C12P21/08 ,  C07K16/28 ,  C12N9/24 ,  C07K16/30 ,  C12N15/62 ,  C12N9/10 ,  C07K16/32 ,  C12P21/00 ,  A61K38/00 ,  A61K39/00

CPC分类号： C07K16/2887 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2319/05 ,  C12N9/1051 ,  C12N9/2488 ,  C12N15/62 ,  C12P21/005 ,  C12Y204/01038 ,  C12Y204/01144 ,  C12Y302/01024 ,  C12Y302/01096 ,  C12Y302/01114

摘要： The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

摘要翻译： 本发明涉及蛋白质的糖基化工程领域。 更具体地说，本发明涉及具有催化活性的核酸分子，包括具有催化活性的核糖分子，以及其在宿主细胞的糖基化工程中的用途，以产生具有改善的治疗性质的多肽，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

公开(公告)号：US20090010921A1

公开(公告)日：2009-01-08

申请号：US11889975

申请日：2007-08-17

申请人： Pablo Umana ,  Peter Brunker ,  Claudia Ferrara ,  Tobias Suter ,  Ursula Puntener ,  Ekkehard Mossner

发明人： Pablo Umana ,  Peter Brunker ,  Claudia Ferrara ,  Tobias Suter ,  Ursula Puntener ,  Ekkehard Mossner

IPC分类号： A61K39/395 ,  C07K16/46 ,  C07K16/28 ,  C07K14/00

CPC分类号： C07K16/2887 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/01 ,  C12N9/1051 ,  C12N15/11 ,  C12N15/63 ,  C12Y204/01144 ,  Y10S530/808 ,  Y10S530/866 ,  Y10S530/867

摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

摘要翻译： 本发明涉及抗原结合分子（ABM）。 在具体实施方案中，本发明涉及重组单克隆抗体，包括对人CD20特异性的嵌合，灵长类或人源化抗体。 此外，本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

公开(公告)号：US20040241817A1

公开(公告)日：2004-12-02

申请号：US10761435

申请日：2004-01-22

申请人： GlycArt Biotechnology AG

发明人： Pablo Umana ,  Peter Bruenker ,  Claudia Ferrara ,  Tobias Suter

IPC分类号： C12N009/10 ,  C07H021/04

CPC分类号： C07K16/2887 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2319/05 ,  C12N9/1051 ,  C12N9/2488 ,  C12N15/62 ,  C12P21/005 ,  C12Y204/01038 ,  C12Y204/01144 ,  C12Y302/01024 ,  C12Y302/01096 ,  C12Y302/01114

摘要： The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

摘要翻译： 本发明涉及蛋白质的糖基化工程领域。 更具体地说，本发明涉及具有催化活性的核酸分子，包括具有催化活性的核糖分子，以及其在宿主细胞的糖基化工程中的用途，以产生具有改善的治疗性质的多肽，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

公开(公告)号：US09296820B2

公开(公告)日：2016-03-29

申请号：US10981738

申请日：2004-11-05

申请人： Pablo Umaña ,  Peter Brünker ,  Claudia Ferrara Koller ,  Tobias Suter ,  Ursula Püntener ,  Ekkehard Mössner

发明人： Pablo Umaña ,  Peter Brünker ,  Claudia Ferrara Koller ,  Tobias Suter ,  Ursula Püntener ,  Ekkehard Mössner

IPC分类号： C12N15/13 ,  C12N15/64 ,  C12N15/85 ,  C12N5/16 ,  C07K16/28 ,  C12N15/11 ,  C12N15/63 ,  A61K39/00

CPC分类号： C07K16/2887 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/01 ,  C12N9/1051 ,  C12N15/11 ,  C12N15/63 ,  C12Y204/01144 ,  Y10S530/808 ,  Y10S530/866 ,  Y10S530/867

摘要： The present invention relates to nucleic acids encoding anti-CD20 antigen binding molecules (ABMs). In particular embodiments, the present invention relates to nucleic acid encoding recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In some embodiments, the invention relates to an isolated polynucleotide comprising a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:40; SEQ ID NO:32; SEQ ID NO:56; and SEQ ID NO:60; and b) a sequence encoding a polypeptide having the sequence of SEQ ID NO:76. In addition, the present invention relates to vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

摘要翻译： 本发明涉及编码抗CD20抗原结合分子（ABM）的核酸。 在具体实施方案中，本发明涉及编码重组单克隆抗体的核酸，包括对人CD20特异性的嵌合，灵长类或人源化抗体。 在一些实施方案中，本发明涉及分离的多核苷酸，其包含a）编码具有选自SEQ ID NO：40的序列的多肽的序列; SEQ ID NO：32; SEQ ID NO：56; 和SEQ ID NO：60; 和b）编码具有SEQ ID NO：76的序列的多肽的序列。 此外，本发明涉及包含这种核酸分子的载体和宿主细胞。 本发明还涉及用于生产本发明的ABM的方法。 此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

公开(公告)号：US20160076009A1

公开(公告)日：2016-03-17

申请号：US14815583

申请日：2015-07-31

申请人： ROCHE GLYCART AG

发明人： Pablo UMAÑA ,  Peter BRÜNKER ,  Claudia FERRARA KOLLER ,  Tobias SUTER ,  Ursula PÜNTENER ,  Ekkehard MÖSSNER

IPC分类号： C12N9/10 ,  C07K16/28

CPC分类号： C07K16/2887 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/01 ,  C12N9/1051 ,  C12N15/11 ,  C12N15/63 ,  C12Y204/01144 ,  Y10S530/808 ,  Y10S530/866 ,  Y10S530/867

摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

公开(公告)号：US20160075794A1

公开(公告)日：2016-03-17

申请号：US14815604

申请日：2015-07-31

申请人： Roche Glycart AG

发明人： Pablo UMAÑA ,  Peter Brünker ,  Claudia FERRARA KOLLER ,  Tobias SUTER ,  Ursula Püntener ,  Ekkehard Mössner

IPC分类号： C07K16/28

CPC分类号： C07K16/2887 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/01 ,  C12N9/1051 ,  C12N15/11 ,  C12N15/63 ,  C12Y204/01144 ,  Y10S530/808 ,  Y10S530/866 ,  Y10S530/867

摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

公开(公告)号：US08932825B2

公开(公告)日：2015-01-13

申请号：US10500240

申请日：2002-12-24

申请人： Stefan Wildt ,  Robert Gordon Miele ,  Juergen Hermann Nett ,  Robert C. Davidson

发明人： Stefan Wildt ,  Robert Gordon Miele ,  Juergen Hermann Nett ,  Robert C. Davidson

IPC分类号： G01N33/569 ,  C12P1/02 ,  C12N1/00 ,  A61K51/00 ,  C12N9/10 ,  C12P21/00

CPC分类号： C12N15/815 ,  A01K2217/075 ,  C07K14/705 ,  C07K2319/05 ,  C12N9/1051 ,  C12N9/2402 ,  C12P21/005 ,  C12Y204/01143 ,  C12Y204/01144 ,  C12Y204/01145 ,  C12Y204/01155 ,  C12Y302/01024

摘要： The present invention relates to host cells having modified lipid-linked oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells have a GlcNAcMan3GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g., glycosyl-transferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.

摘要翻译： 本发明涉及具有经修饰的脂质连接的寡糖的宿主细胞，其可通过异源表达一组糖基转移酶，糖转运体和甘露糖苷酶进一步修饰，以成为用于产生哺乳动物例如人治疗性糖蛋白的宿主菌株。 该方法提供了可用于表达和靶向参与糖基化的任何所需基因的工程化宿主细胞。 制备或选择具有修饰的脂质连接寡糖的宿主细胞。 在工程化的宿主细胞中制备的N-聚糖具有GlcNAcMan3GlcNAc2核心结构，然后可以通过异源表达一种或多种酶，例如糖基转移酶，糖转运蛋白和甘露糖苷酶来进一步修饰，以产生人样糖蛋白。 为了生产治疗性蛋白质，该方法可适用于工程化可能获得任何所需糖基化结构的细胞系。